Does Haemonetics (HAE) Have Enduring Growth Potential?

1 hour ago 1

Soumya Eswaran

Thu, May 21, 2026 astatine 9:48 AM CDT 3 min read

Aristotle Capital Boston, LLC, an concern advisor, released its first-quarter 2026 capitalist missive for “Small Cap Equity Fund”. A transcript of the missive is disposable to download here. U.S. small-cap equities delivered beardown show successful the archetypal 4th amid macroeconomic and geopolitical volatility, outpacing large-cap stocks. Improving earnings, charismatic comparative valuations, and a absorption connected home sectors supported the tiny caps successful the quarter. In this backdrop, the Aristotle Small Cap Equity Fund (Class I-2) delivered a full instrumentality of 1.50% successful the quarter, outperforming the Russell 2000 Index’s 0.89% return. The show was supported by information enactment successful the accusation exertion and financials sectors, on with underweight allocations to healthcare and industrials. The money remains optimistic astir the semipermanent outlook for U.S. small-cap equities. Please reappraisal the Strategy’s apical 5 holdings to summation insights into their cardinal selections for 2026.

In its first-quarter 2026 capitalist letter, Aristotle Small Cap Equity Fund highlighted stocks similar Haemonetics Corporation (NYSE:HAE). Haemonetics Corporation (NYSE:HAE) is an innovative aesculapian exertion institution that provides solutions for improving diligent care. On April 20, 2026, Haemonetics Corporation (NYSE:HAE) closed astatine $59.56 per share. One-month instrumentality of Haemonetics Corporation (NYSE:HAE) was 0.10%, and its shares mislaid 9.98% implicit the past 52 weeks. Haemonetics Corporation (NYSE:HAE) has a marketplace capitalization of $2.71 billion.

Aristotle Small Cap Equity Fund stated the pursuing regarding Haemonetics Corporation (NYSE:HAE) successful its Q1 2026 capitalist letter:

"Haemonetics Corporation (NYSE:HAE) is simply a planetary supplier of hematology and humor absorption products and solutions. The company’s shares weakened pursuing its net release, contempt results beating expert expectations. Investor absorption was driven by a reported year-over-year gross diminution tied to planned portfolio transitions which overshadowed coagulated underlying request and borderline expansion. We judge that the company’s beardown competitory presumption wrong the plasmapheresis marketplace on with accrued concern successful probe and improvement should make worth for shareholders implicit a multi-year period."

Is Haemonetics Corporation (HAE) the Best Russell 2000 Stock to Buy According to Wall Street Analysts?

Haemonetics Corporation (NYSE:HAE) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 33 hedge money portfolios held Haemonetics Corporation (NYSE:HAE) astatine the extremity of the 4th quarter, compared to 36 successful the erstwhile quarter. Haemonetics Corporation (NYSE:HAE) reported revenue of $346 cardinal successful the 4th fourth of 2026, an summation of 5% connected a reported and 9% connected an integrated basis. While we admit the imaginable of Haemonetics Corporation (NYSE:HAE) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article